Alona Muzikansky
Harvard University
301 Papers
817 Citations
Alona Muzikansky is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 72, co-authored 254 publications. Previous affiliations of Alona Muzikansky include Utrecht University & Shriners Hospitals for Children.
Chat about Author
Papers
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Jennifer S. Temel,Joseph A. Greer,Alona Muzikansky,Emily R. Gallagher,Sonal Admane,Vicki A. Jackson,Constance Dahlin,Craig D. Blinderman,Juliet Jacobsen,William F. Pirl,J. Andrew Billings,Thomas J. Lynch +11 more
TL;DR: Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood and, as compared with patients receiving standard care, patients received less aggressive care at the end of life but longer survival.
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Shyamala Maheswaran,Lecia V. Sequist,Sunitha Nagrath,Lindsey Ulkus,Brian W. Brannigan,Chey V. Collura,Elizabeth J. Inserra,Sven Diederichs,A. John Iafrate,Daphne W. Bell,Subba R. Digumarthy,Alona Muzikansky,Alona Muzikansky,Daniel Irimia,Jeffrey Settleman,Ronald G. Tompkins,Ronald G. Tompkins,Thomas J. Lynch,Mehmet Toner,Mehmet Toner,Daniel A. Haber,Daniel A. Haber +21 more
TL;DR: Molecular analysis of circulating tumor cells from the blood of patients with lung cancer offers the possibility of monitoring changes in epithelial tumor genotypes during the course of treatment, and shows that a reduction in the number of captured cells was associated with a radiographic tumor response; an increase in theNumber of cells wasassociated with tumor progression, with the emergence of additional EGFR mutations in some cases.
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Lecia V. Sequist,Renato G. Martins,David R. Spigel,Steven M. Grunberg,Alexander I. Spira,Pasi A. Jänne,Victoria A. Joshi,David McCollum,Tracey L. Evans,Alona Muzikansky,Georgiana Kuhlmann,Moonjoo Han,Jonathan S. Goldberg,Jeffrey Settleman,A. John Iafrate,Jeffrey A. Engelman,Daniel A. Haber,Bruce E. Johnson,Thomas J. Lynch +18 more
TL;DR: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance, and should be compared with combination chemotherapy.
875
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial
Jennifer S. Temel,Joseph A. Greer,Areej El-Jawahri,William F. Pirl,Elyse R. Park,Vicki A. Jackson,Anthony L. Back,Mihir Kamdar,Juliet Jacobsen,Eva Chittenden,Simone Rinaldi,Emily R. Gallagher,Justin Eusebio,Zhigang Li,Alona Muzikansky,David P. Ryan +15 more
TL;DR: For patients with newly diagnosed incurable cancers, early integrated PC improved quality of life and other salient outcomes, with differential effects by cancer type.
742